Bass’s First IPR Decision Rendered – Victory for Patent Owner, Shire Lpc

By Tom Engellenner If Kyle Bass’s Coalition for Affordable Drugs Series II hedge fund was hoping to reap a windfall from short positions in Shire Plc’s stock this week, it was dealt a major setback by a Patent Trial and Appeal Board (PTAB) decision to uphold Shire’s patent on its colitis drug, Lialda®.  In a … Continue reading Bass’s First IPR Decision Rendered – Victory for Patent Owner, Shire Lpc

Bass Continues Fishing; Pharma Seeks Sanctuary

By Tom Engellenner It’s time for an update on Kyle Bass’s efforts to rid America of the pharmaceutical patents that support high priced drugs.  Between February and September 2015, at least eleven investment funds organized by J. Kyle Bass and Erich Spangenberg (the Coalitions for Affordable Drugs Series I - XI) filed nearly three dozen … Continue reading Bass Continues Fishing; Pharma Seeks Sanctuary

Hedge Fund Troll Undetered by Initial Setbacks

By Tom Engellenner Kyle Bass and his hedge funds, the Coalitions for Affordable Drugs LLC, have failed in several of their initial attempts to knock out drug patents. (See our prior article detailing the first seven hedge funds formed by Bass to challenge various pharmaceutic companies.) In two decisions handed down late last month, the … Continue reading Hedge Fund Troll Undetered by Initial Setbacks